204 related articles for article (PubMed ID: 18790445)
1. Peptide vaccines for myeloid leukaemias.
Dao T; Scheinberg DA
Best Pract Res Clin Haematol; 2008 Sep; 21(3):391-404. PubMed ID: 18790445
[TBL] [Abstract][Full Text] [Related]
2. [Immunotherapy and cell therapy for myeloid leukemia].
Yasukawa M
Nihon Rinsho; 2009 Oct; 67(10):1938-43. PubMed ID: 19860194
[TBL] [Abstract][Full Text] [Related]
3. Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias.
Barrett AJ; Rezvani K
Clin Exp Immunol; 2007 May; 148(2):189-98. PubMed ID: 17437417
[TBL] [Abstract][Full Text] [Related]
4. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.
Volpe G; Cignetti A; Panuzzo C; Kuka M; Vitaggio K; Brancaccio M; Perrone G; Rinaldi M; Prato G; Fava M; Geuna M; Pautasso M; Casnici C; Signori E; Tonon G; Tarone G; Marelli O; Fazio VM; Saglio G
Cancer Res; 2007 Jun; 67(11):5300-7. PubMed ID: 17545610
[TBL] [Abstract][Full Text] [Related]
5. The abl/bcr gene product as a novel leukemia-specific antigen: peptides spanning the fusion region of abl/bcr can be recognized by both CD4+ and CD8+ T lymphocytes.
Wagner WM; Ouyang Q; Pawelec G
Cancer Immunol Immunother; 2003 Feb; 52(2):89-96. PubMed ID: 12594572
[TBL] [Abstract][Full Text] [Related]
6. A novel MHC-associated proteinase 3 peptide isolated from primary chronic myeloid leukaemia cells further supports the significance of this antigen for the immunotherapy of myeloid leukaemias.
Knights AJ; Weinzierl AO; Flad T; Guinn BA; Mueller L; Mufti GJ; Stevanovic S; Pawelec G
Leukemia; 2006 Jun; 20(6):1067-72. PubMed ID: 16628186
[TBL] [Abstract][Full Text] [Related]
7. Tumour antigen-targeted immunotherapy for chronic myeloid leukaemia: is it still viable?
Riley CL; Mathieu MG; Clark RE; McArdle SE; Rees RC
Cancer Immunol Immunother; 2009 Sep; 58(9):1489-99. PubMed ID: 19259670
[TBL] [Abstract][Full Text] [Related]
8. Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules.
Schmitt M; Li L; Giannopoulos K; Chen J; Brunner C; Barth T; Schmitt A; Wiesneth M; Döhner K; Döhner H; Greiner J
Exp Hematol; 2006 Dec; 34(12):1709-19. PubMed ID: 17157168
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapeutic targeting of Wilms' tumor protein.
Hutchings Y; Osada T; Woo CY; Clay TM; Lyerly HK; Morse MA
Curr Opin Mol Ther; 2007 Feb; 9(1):62-9. PubMed ID: 17330403
[TBL] [Abstract][Full Text] [Related]
10. BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia.
Grünebach F; Mirakaj V; Mirakaj V; Müller MR; Brümmendorf T; Brossart P
Cancer Res; 2006 Jun; 66(11):5892-900. PubMed ID: 16740729
[TBL] [Abstract][Full Text] [Related]
11. [Immunotherapy targeting the Wilms' tumor 1 gene product for patients with malignant brain tumors].
Hashimoto N; Tsuboi A; Chiba Y; Izumoto S; Oka Y; Yoshimine T; Sugiyama H
Brain Nerve; 2009 Jul; 61(7):805-14. PubMed ID: 19618858
[TBL] [Abstract][Full Text] [Related]
12. The Wilms' tumor antigen is a novel target for human CD4+ regulatory T cells: implications for immunotherapy.
Lehe C; Ghebeh H; Al-Sulaiman A; Al Qudaihi G; Al-Hussein K; Almohareb F; Chaudhri N; Alsharif F; Al-Zahrani H; Tbakhi A; Aljurf M; Dermime S
Cancer Res; 2008 Aug; 68(15):6350-9. PubMed ID: 18676860
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapeutic strategies in chronic myeloid leukemia.
Clark RE
Curr Hematol Malig Rep; 2007 May; 2(2):89-94. PubMed ID: 20425356
[TBL] [Abstract][Full Text] [Related]
14. Evidence that a BCR-ABL fusion peptide does not induce lymphocyte proliferation or cytokine production in vitro.
Abu-Eisha HM; Butt NM; Clark RE; Christmas SE
Leuk Res; 2007 Dec; 31(12):1675-81. PubMed ID: 17324459
[TBL] [Abstract][Full Text] [Related]
15. Peptide vaccines for patients with acute myeloid leukemia.
Schmitt M; Casalegno-Garduño R; Xu X; Schmitt A
Expert Rev Vaccines; 2009 Oct; 8(10):1415-25. PubMed ID: 19803762
[TBL] [Abstract][Full Text] [Related]
16. [Promise of immunotherapy of the chronic myeloid leukaemia].
Vonka V
Cas Lek Cesk; 2005; 144(3):172-6. PubMed ID: 15887400
[TBL] [Abstract][Full Text] [Related]
17. Clinical peptide vaccination trials for leukemia patients.
Casalegno-Garduño R; Schmitt A; Schmitt M
Expert Rev Vaccines; 2011 Jun; 10(6):785-99. PubMed ID: 21692700
[TBL] [Abstract][Full Text] [Related]
18. Immunogenic antigens as therapeutic targets against myeloid leukaemic cells.
Hofmann S; Greiner J
Leuk Res; 2010 Jul; 34(7):850-1. PubMed ID: 20359745
[TBL] [Abstract][Full Text] [Related]
19. WT1 peptide vaccine for the treatment of cancer.
Oka Y; Tsuboi A; Oji Y; Kawase I; Sugiyama H
Curr Opin Immunol; 2008 Apr; 20(2):211-20. PubMed ID: 18502632
[TBL] [Abstract][Full Text] [Related]
20. Current status of vaccination therapy for leukemias.
Reichardt VL; Brossart P
Curr Hematol Rep; 2005 Jan; 4(1):73-6. PubMed ID: 15610663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
